On August 27, ZAI LAB rose 5.17% in regular trading, trading at HK$21.18/share, with turnover of HK$183 million.

On the news front, the company released its interim results on August 26. First-half total revenue reached $206 million, with net product revenue of $201 million, down 6% year-over-year, primarily due to Zejula revenue decline from generic olparib entering centralized procurement and Nuvaira price adjustments related to national medical insurance renewal. Net loss widened 14% to $102 million, driven by increased licensing fees pushing R&D expenses up to $127 million. However, Dingyoule and Niuzaile sales growth partially offset the declines.

Additionally, RTW Investments acquired approximately 12.3 million shares on August 20 at an average price of $26 per share, investing approximately $320 million and raising its stake to 8.25% from 7.17%. Guotai Haitong Securities maintained an Overweight rating, noting that growth momentum is shifting toward new drugs, with core focus on Zoci registration trial progress and ZL-1503 first-in-human data.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)